Advancing Care Across the Spectrum of Pancreatic Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Pancreatic Cancer

Current Treatment for Pancreatic Cancer Is Insufficient

First-Line Treatment of Metastatic Pancreatic Cancer

First-Line Gemcitabine

FOLFIRINOX for First-Line Treatment

Phase 3 IMPACT Trial Gemcitabine + nab-Paclitaxel

Selection of First-Line Treatment According to Clinical Features

Second-Line Treatment of Metastatic Pancreatic Cancer

Phase 3 NAPOLI-1 Trial Study Design

NAPOLI-1 Trial Results

Treatment Sequencing in Pancreatic Cancer

Role of Oxaliplatin in Second-Line Treatment

Emerging Therapies for Advanced Pancreatic Cancer

Immunotherapy

PARP Inhibitors

Veliparib in Pancreatic Cancer

Molecular Testing in Pancreatic Cancer

Advances in Early-Stage Pancreatic Cancer

Phase 3 PRODIGE 24/CCTG PA.6

PRODIGE 24/CCTG PA.6 Key Results

LAPACT Trial

LAPACT Trial Results

PREOPANC Study Design

PREOPANC Key Results

Take-Home Messages

Abbreviations

Abbreviations (cont)

Abbreviations (cont)